Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Debt Issuances (2016 - 2017)

Historic Long-Term Debt Issuances for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q4 2017 value amounting to $41000.0.

  • Lineage Cell Therapeutics' Long-Term Debt Issuances fell 9324.55% to $41000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $425000.0, marking a year-over-year decrease of 7581.1%. This contributed to the annual value of $425000.0 for FY2017, which is 7581.1% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Long-Term Debt Issuances of $41000.0 as of Q4 2017, which was down 9324.55% from $85000.0 recorded in Q3 2017.
  • In the past 5 years, Lineage Cell Therapeutics' Long-Term Debt Issuances registered a high of $1.0 million during Q2 2016, and its lowest value of $4000.0 during Q4 2014.
  • In the last 4 years, Lineage Cell Therapeutics' Long-Term Debt Issuances had a median value of $127000.0 in 2016 and averaged $272000.0.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Long-Term Debt Issuances surged by 157500.0% in 2015, and later plummeted by 9324.55% in 2017.
  • Over the past 4 years, Lineage Cell Therapeutics' Long-Term Debt Issuances (Quarter) stood at $4000.0 in 2014, then skyrocketed by 1575.0% to $67000.0 in 2015, then soared by 805.97% to $607000.0 in 2016, then crashed by 93.25% to $41000.0 in 2017.
  • Its Long-Term Debt Issuances was $41000.0 in Q4 2017, compared to $85000.0 in Q3 2017 and $176000.0 in Q2 2017.